Leal-Cerro Alfonso, Soto Moreno Alfonso, Mangas Miguel Angel, León Justel Antonio, Webb Susan
Instituto de Biomedicina de Sevilla. I/CSIC/Universidad de Sevilla y Unidad de Gestión de Endocrinología. Hospital Universitario Virgen del Rocío. Sevilla. España.
Endocrinol Nutr. 2009 Apr;56(4):187-94. doi: 10.1016/S1575-0922(09)70983-0. Epub 2009 Jun 11.
Cushing's syndrome results from prolonged exposure to excessive circulating glucocorticosteroids and is associated with significant morbidity and mortality. While the treatment of choice in most patients is surgical, the metabolic consequences of this syndrome, including hypertension and diabetes mellitus, increase the risks of such surgery. Hypercortisolemia and its sequelae can be efficiently reversed or controlled using medical therapy, either as a temporary measure prior to definitive treatment or as a longer-term treatment in some particularly difficult cases. Drug treatment has been targeted at the hypothalamic/pituitary level, the adrenal glands and at glucocorticoid receptors. The present review discusses the pharmacotherapeutic agents that have been used in Cushing's syndrome and the criteria for their use, as well as recent drugs that may improve the medical treatment of this complex endocrinological disorder in the future. Finally, the short-and long-term follow-up of patients with Cushing's syndrome after surgery is also discussed.
库欣综合征是由于长期暴露于过量循环的糖皮质激素引起的,与显著的发病率和死亡率相关。虽然大多数患者的首选治疗方法是手术,但该综合征的代谢后果,包括高血压和糖尿病,会增加此类手术的风险。高皮质醇血症及其后遗症可以通过药物治疗有效地逆转或控制,既可以作为确定性治疗前的临时措施,也可以作为某些特别困难病例的长期治疗方法。药物治疗的靶点是下丘脑/垂体水平、肾上腺以及糖皮质激素受体。本综述讨论了用于库欣综合征的药物治疗药物及其使用标准,以及未来可能改善这种复杂内分泌疾病药物治疗的新型药物。最后,还讨论了库欣综合征患者术后的短期和长期随访情况。